Skip to content
newprotein.net Explore ingredients
Menu
Illustrated cell-culture laboratory with a bioreactor, scaffold and a cultivated chicken fillet

Cultured meat: cell lines, growth media, cost and approvals

Introduction to cultured meat: cell lines, serum-free growth media, scaffolds, bioreactor scale-up, techno-economic cost models and approvals by country.

By the New Protein editorial team · Reviewed · 13 min read

What cultured meat is and how it is made

Cultured meat is animal tissue grown from cells in a controlled vessel instead of inside a living animal. The Singapore Food Agency describes growing animal cells, such as chicken or shrimp, in a bioreactor with culture media, sometimes onto edible scaffolds that give shape and texture. The result is a cell mass that is harvested and turned into food.

The production chain has five stages. Cells are sourced and characterised, expanded in suspension or on carriers, differentiated into muscle, fat or connective cells, harvested, and formulated into a finished product. Reviews of the field identify seed cell acquisition, serum-free media, bioreactor scale-up, three-dimensional tissue formation and sensory quality as the areas where technology has advanced and where hurdles remain.

Terminology varies by market, and buyers should match it to local law. Cultivated meat, cell-cultured meat, cell-based meat and cultured meat all describe the same family of products, and regulators write their own labels into standards. Australia and New Zealand require the words cell-cultured or cell-cultivated, for example, which means packaging copy and marketing claims need market-specific review.

The category is broader than beef or chicken. The site covers cultivated meat as a class, with separate pages on cultivated chicken, cultivated beef, cultivated fat and cultivated seafood. Fat, in particular, is attractive because it carries flavour and may need less structure than muscle to be useful in blends.

Cultured meat differs from precision fermentation and plant-based meat in what is being made. Precision fermentation produces single proteins such as heme, which can be added to analogues. Plant-based products assemble plant ingredients into meat-like structures. Cultivated products grow actual animal cells, so the safety dossier resembles a tissue engineering file, with cell identity and banking at its centre.

Cell lines and cell banking

Everything starts with the cells. The choice of species, tissue, cell type and lineage determines growth rate, differentiation ability and the final texture and flavour. Stem cells from muscle, embryonic-like cells and engineered lines are all explored, and reviews describe progress in cell sourcing and line engineering as a prerequisite for cost reduction and consistent quality.

Cell lines used for production must be characterised and stable. FDA states that its consultation reviews the production process and the cell material, including cell lines, cell banks, manufacturing controls and inputs. Buyers should expect a supplier to hold a documented master cell bank, with identity, purity and genetic stability testing and a defined passage limit.

A 2025 article in Nature Food argues for a risk-based approach to cell line development and banking, drawing on neighbouring fields and case studies of public dossiers from UPSIDE Foods, GOOD Meat and Vow. Its main point is that quality control and safety assurance for cell lines and food-grade cell banks must be standardised before production scales up.

Immortalisation and genetic engineering raise regulatory questions. Immortalised or engineered lines can grow indefinitely and tolerate suspension culture, which helps cost, but regulators ask about genetic stability and about any selection markers or integrated sequences. A supplier should be able to explain how its lines were derived, what changes were made and how unwanted changes are monitored.

Species and tissue matter for allergens and labelling. Cells of a given species express that species’ proteins, so cultured chicken, fish and crustacean products carry the corresponding allergenic risk. Buyers should require species-specific allergen statements and ask for documentation on any residual medium proteins, including growth factors and carrier proteins that could remain after harvest and washing.

Growth media and why they dominate cost

Growth medium supplies the nutrients that cells consume and the signals that tell them to divide or differentiate. Humbird’s 2021 analysis names amino acids and protein growth factors as high-cost inputs, since pure grades are expensive, and discusses plant protein hydrolysates as a substitute. It concludes that such replacement needs further study and is necessary but insufficient.

Serum-free media are the industry direction. Reviews list serum-free media cost reduction among the critical breakthroughs for scaling, and regulators ask whether any animal-derived components remain. Ask suppliers whether fetal bovine serum was used in cell isolation, banking or growth, because a product marketed as free of animal slaughter may still depend on serum at an early stage.

Animal-free media can be cheap in principle. A 2024 study in Nature Food reported an animal-component-free medium costing USD 0.63 per litre that supported long-term, high-density culture of chicken cells, with up to 130 million cells per millilitre. Those figures describe one experimental system, but they show how far medium cost can fall when growth factors are replaced.

Recombinant growth factors link cultured meat to precision fermentation. Growth factors made in microbial hosts are one route to lower medium cost, and a 2026 review of biomass and precision fermentation inputs for cultivated meat examines advances, sustainability, food safety and techno-economic perspectives. Ask where growth factors come from and what residual host proteins they carry.

Plant-based media components are another route. A 2024 scoping review of techno-economic analyses notes that scale-up feasibility may hinge on cost-saving areas such as plant-based media components, food-grade aseptic conditions and the scaling of related supply chains. Any medium containing hydrolysates introduces its own allergen and variability questions, such as soy or pea protein sources and batch-to-batch composition.

Scaffolds, structure and hybrid products

Muscle cells grown in suspension form unstructured mass, which suits minced products, sausages and nuggets. Whole-cut products need structure, so researchers study scaffolds that guide cells into aligned fibres. The Singapore Food Agency refers to edible scaffolds, and the 2026 review of cellular agriculture lists edible scaffolds among the critical breakthroughs required alongside cell line optimisation and cheaper media.

Scaffold materials must be food safe and affordable. Candidates include plant proteins, polysaccharides and fibres, each with properties that affect cell attachment and final texture. Check the allergen status of the scaffold, since a soy, pea or wheat protein scaffold would require declaration, and ask whether the scaffold is eaten with the product or removed before harvest.

Hybrid products reduce the amount of cultivated cell mass needed. A cultured cell paste combined with plant protein, fat and binders can deliver meat-like flavour and nutrition at a lower cell cost per kilogram. The Australian authorisation reflects this model, permitting cultured quail cells to be used with other ingredients in products such as logs, rolls and patties.

Plant protein partners shape hybrid quality. Textured plant proteins provide fibrous structure and water binding, and ingredients such as textured pea protein can carry the bulk of a formula while cells add flavour and species-specific character. Formulators should test cooking loss, binding and flavour release, because cell paste and plant protein can behave differently in heat and shear.

Heme and fat can lift a hybrid. Precision-fermented myoglobin offers colour and meaty aroma that cell paste may lack, while cultivated fat adds flavour and mouthfeel. Each added ingredient needs its own approval in the target market, so complexity increases regulatory workload and should be weighed against the sensory gain.

Bioreactors and scale-up

Bioreactor scale defines whether cultured meat can reach food volumes. Humbird argues that low growth rate, metabolic inefficiency, catabolite inhibition and shear-induced damage limit practical bioreactor volume and attainable cell density, and that equipment with adequate contamination safeguards has high capital cost. These constraints explain why pharmaceutical-scale facilities do not translate directly to meat production.

Reactor design options include stirred tanks, airlift reactors and perfusion systems. A 2023 techno-economic study modelled stirred tanks of roughly 42,000 and 211,000 litres and a 262,000 litre airlift reactor, and a 2024 study modelled a 50,000 litre perfusion facility. Each design trades off mixing, oxygen supply, shear and capital, so ask which underlies capacity claims.

Continuous and perfusion processes aim to raise cell density and productivity. The Nature Food study described tangential flow filtration achieving up to 130 million cells per millilitre and multiple harvests over more than 20 days. Such results are encouraging, but they come from one system and have not been demonstrated at the volumes assumed in the cost model.

Cell density and harvest yield determine product price. At high cell density, the cell mass can reach a large share of working volume, which reduces medium and capital cost per kilogram. The Nature Food abstract reports yields of 43 percent weight per volume, and techno-economic reviews therefore treat density and perfusion as the key levers for reaching competitive prices.

Capacity today remains pilot or demonstration scale in most cases. A buyer should treat announcements of large facilities as plans until commissioning data and production volumes are shown. Request evidence of actual output per batch, number of runs completed, yields, failure rates, and the volume that can be supplied under contract within the next two years.

Cost and price parity: what the models say

Published techno-economic models give a wide range. Humbird’s 2021 analysis, based on fermentation and biopharmaceutical practice, concluded that capital and operating costs would likely preclude affordability as food. By contrast, a 2023 model for 100 million kilograms a year found cost of goods sold of USD 35, 25 and 17 per kilogram for three reactor designs.

Assumptions explain the gap. The 2023 model assumed several facilities producing 100,000,000 kg of cultured beef per year, about 0.14 percent of global beef production, and relied on large reactors and lower media costs. The authors stress that better bioreactors, alternative reactor designs and cheaper media are necessary for commercialisation. Each assumption is a lever for sensitivity analysis.

Empirical data are starting to feed models. The 2024 Nature Food analysis used measured cell densities and a medium priced at USD 0.63 per litre to estimate that cultivated chicken could fall to USD 6.2 per pound in a 50,000 litre facility, within the range of organic chicken. The authors note that other variables would also affect market prices.

A 2024 scoping review offers a sober synthesis. It states that techno-economic analyses to date show cultivated meat is unlikely to compete with conventional meat on cost under the current technological paradigm, and that feasibility may hinge on plant-based media components, food-grade aseptic conditions and supply chain scaling. It also calls for research on serum-free differentiation and new bioreactor designs.

Buyers should treat quoted prices as strategic rather than cost-based. Early products sell at a premium or as small inclusions in hybrid formats, which lowers the cost impact per portion. A procurement team should ask for a cost roadmap with explicit assumptions on medium price, cell density, reactor size and yield, and then compare it with the techno-economic literature.

Food safety and quality specifications

Safety begins with hazard analysis. Cultivated meat avoids slaughter-related enteric pathogens, which gives it a theoretical microbiological advantage, but a 2025 review notes that limited data exist to validate this. Cell culture is vulnerable to contamination, and an industry survey in the review reported an average batch failure rate of 11.2 percent, mostly bacteria from personnel, equipment and environment.

Existing systems provide most of the controls. The review argues that combinations of HACCP, good manufacturing practice and good cell culture practice can address the main hazards, and that microbiological issues should be surmountable as the sector matures. It also calls for studies on how microbes grow in different cultivated products, given differences in pH, water activity and background flora.

Regulators set specific microbial standards. FSANZ introduced food safety standard 3.4.1, which covers controls on inputs, equipment, premises and monitoring for cell-cultured foods, and Schedule 27 sets microbiological limits for Salmonella and Listeria monocytogenes. Buyers can use these as a baseline when writing specifications, even where their own market has not yet published equivalent rules.

A specification for a cultivated ingredient should cover several elements: species and cell type, form and moisture, protein and fat, microbiological limits, residual medium components, allergen statements, heavy metals and residues. Add batch-level identity testing by DNA methods to confirm the species and exclude cross-contamination from other cell lines handled in the same facility.

Traceability and cell bank documentation complete the picture. Request the cell line’s origin, the date and conditions of isolation, any genetic modifications, passage numbers, bank testing results, and the chain of custody from bank to harvest. Without these records, a buyer cannot demonstrate to a regulator or an auditor that the product matches the evaluated material.

Approvals by country: regulatory status of cultured meat

Singapore was first. The Singapore Food Agency’s factsheet records that Eat Just’s cultivated chicken was allowed to be sold as an ingredient in a nugget product from December 2020, under a framework introduced in November 2019 that requires pre-market allowance for novel food. Offence provisions for supply without approval have applied since 28 November 2025.

In the United States, FDA runs a voluntary pre-market consultation. Its page lists a first consultation completed on 16 November 2022 for cultured chicken cell material, a second on 21 March 2023, and one on 7 March 2025 for food made with cultured pork fat cells. A 2026 review adds that USDA authorised commercial sale in 2023.

Oversight in the United States is split by stage. For livestock and poultry, FDA oversees cell collection, cell banks and cell growth and differentiation, and responsibility transfers to USDA-FSIS at harvest. USDA-FSIS then oversees further production and must approve labelling. For species outside USDA jurisdiction, such as seafood, FDA is responsible, so cultivated fish follows a different path.

Australia and New Zealand approved cultured quail from Vow Group in June 2025. FSANZ gazetted amendments on 18 June 2025, after an assessment with two public consultations, and added a Schedule 25A listing permitted cell-cultured foods. Approvals under the standard are product specific, so other applicants still need individual assessment, and labels must say cell-cultured or cell-cultivated.

The European Union has not approved any animal-origin cell culture-derived food. Gourmey filed the first application in July 2024, for cultivated duck cells intended as foie gras, and Mosa Meat filed for cultivated beef fat in January 2025. EFSA states that none has been approved for sale. Five cell culture-derived foods from plant cells are already on the EU market.

Other countries are developing frameworks, and a buyer should not assume reciprocity. Each jurisdiction defines novel food, assigns responsibilities between agencies, sets labelling rules, and may restrict which species or products are allowed. Verify status per market with local counsel before committing, and treat any announcement of approvals as unconfirmed until the regulator’s own page or gazette confirms it.

Buying and sourcing cultivated ingredients

Procurement for cultivated products is early-stage. Most suppliers sell small volumes into restricted markets, and many deals are co-development or pilot supply. Define what you need clearly: species, form, minimum cell content for a hybrid, target market and labelling, and whether the supplier can provide the regulatory documents your market requires to place the product on sale.

Ask for the regulatory file, not just the headline. A supplier should be able to share which markets have approved the product, the scope of each approval, any conditions of use, and the date. Where approvals depend on product-specific consultations, such as FDA’s, ask for the response letter or equivalent and confirm that the supplied product matches the scope.

Check the inputs. Request the medium composition at the category level, whether serum or other animal-derived components were used, the source of growth factors, scaffold materials and processing aids, and the allergen status of each. Inputs from precision fermentation or plant hydrolysates change the regulatory and allergen picture, and they can change cost sharply if a supplier switches media mid-contract.

Evaluate manufacturing capability. Ask where production happens, reactor type and scale, run history, contamination failure rates, release testing and the quality system. A supplier whose batch failure rate exceeds the industry average will struggle to meet volume commitments, and one with no data on failures may simply not have enough batches to know.

Contract for change control and for exit. Require notification of changes to cell line, medium, scale-up, site or process, comparability data for each, and rights to terminate or re-source if approvals are withdrawn. Regulators can cancel approvals after material changes, as Singapore’s framework states, so a buyer’s contract should pass this risk back to the party that controls the process.

Formulation and where cultured meat fits

Cultivated cell mass behaves more like fresh meat than a protein isolate. It contains water, protein, fat and connective components, and it follows the same cooking, binding and flavour chemistry as conventional meat. Test cooked yield, juiciness, firmness and colour against a conventional benchmark, because small formulation differences change eating quality noticeably.

Fat and flavour carry the product. Cultivated fat can improve juiciness and aroma in blends, and heme or myoglobin can supply colour and meaty notes. Each added ingredient needs approval in the target market, and each affects the label, so decide early whether the commercial aim is a pure cultivated product or a hybrid with plant protein.

Positioning matters as much as formulation. Early products sell as premium or novelty items, and labelling rules require transparent naming. A launch plan should set expectations around availability, price and the product’s category, and avoid claims about sustainability or animal welfare that are not backed by life-cycle data or by approvals in the specific market.

A staged decision process reduces risk. Confirm the legal route in the target market, shortlist suppliers with documented approvals, run bench trials with actual cell paste, test shelf life and safety in the final matrix, and agree contract terms on supply, specifications, change control and price roadmap. If approvals or capacity are missing, plan a plant-based or fermentation-derived bridge product.

Frequently asked questions

What is cultured meat?

Cultured meat, also called cultivated or cell-based meat, is meat grown from animal cells in a bioreactor with a culture medium rather than from a slaughtered animal. Cells proliferate, then differentiate into muscle or fat, and may be grown on edible scaffolds to give structure before harvest and processing.

Is cultured meat real meat?

It is animal cells of the same species, so its composition resembles conventional meat, but it is made without raising and slaughtering the animal. Regulators treat it as a novel food and require its own safety assessment, and several jurisdictions require labels such as cell-cultured or cell-cultivated.

Is cultured meat on sale anywhere?

Singapore allowed cultivated chicken as an ingredient in a nugget product from December 2020. In the United States, FDA completed pre-market consultations from November 2022 and USDA authorised commercial sale in 2023, according to a 2026 review. Australia and New Zealand gazetted cultured quail in June 2025.

Has the European Union approved cultured meat?

Not yet for animal-origin products. Gourmey filed the first application, for cultivated duck foie gras, in July 2024, and Mosa Meat followed in January 2025 with cultivated beef fat. EFSA states that no such food has been approved for sale in the EU. Five plant-cell foods are on the EU market.

How much does cultured meat cost to make?

Published models disagree. A 2023 model gave a cost of goods sold of USD 35 per kg at 42,000 litre reactors falling to USD 17 per kg in a 262,000 litre airlift reactor, while a 2021 analysis concluded that economics would likely preclude affordability as food. Real prices depend on media and scale.

Why is growth medium so important for cost?

Medium supplies amino acids, sugars and protein growth factors, and Humbird's analysis finds suitably pure amino acids and growth factors expensive. Cheaper plant hydrolysates and recombinant growth factors are being studied. A 2024 study reported an animal-free medium costing USD 0.63 per litre.

Does cultured meat use fetal bovine serum?

Early work used serum, but the field has moved towards serum-free and animal-component-free media, and reviews list serum-free media cost reduction as a critical breakthrough. Any supplier should state whether serum or other animal-derived components are used at any stage, including cell banking.

What are cell lines and cell banks in this context?

A cell line is a population of animal cells that can be propagated for production, and a cell bank is a characterised, stored stock that seeds each batch. FDA reviews cell lines, cell banks, manufacturing controls and inputs, and researchers argue that risk-based quality control should be standardised.

What are scaffolds and are they edible?

Scaffolds are structures on which cells grow to form tissue-like products. The Singapore Food Agency describes growing cells onto edible scaffolds to produce shapes and textures resembling meat. Reviews identify edible scaffolds as a key area of development, with plant proteins among the materials studied.

Is cultured meat safe?

Regulators have completed assessments for specific products in several countries. Reviews note theoretical microbiological advantages because slaughter-related enteric pathogens are avoided, but contamination of cell cultures is a real production risk, with an industry survey reporting an average batch failure rate of 11.2 percent.

Is cultured meat vegan or vegetarian?

No. It is made from animal cells, so it does not meet vegan standards, and many vegetarians avoid it as well. Some processes still use animal-derived inputs, while others aim to be animal-component-free, but the product itself is animal tissue grown in vitro.

How is cultured meat labelled?

In Australia and New Zealand, standard 1.5.4 requires labels to say cell-cultured or cell-cultivated. In the United States, USDA-FSIS must approve labels for livestock and poultry products, while FDA ensures labelling of other species is truthful and not misleading.

Does it need a bioreactor the size of a brewery?

Large vessels are discussed in cost models, such as 42,000 litre stirred tanks or 262,000 litre airlift reactors, but Humbird argues that low growth rates, catabolite inhibition and shear damage limit practical reactor volume and cell density. Perfusion processes at 50,000 litres have also been modelled.

What is hybrid cultured meat?

Hybrid products combine a small share of cultivated cells with plant protein or other ingredients, which reduces cell mass needed per kilogram of product. Australia approved cultured quail for use with other ingredients in logs, rolls and patties, which shows the model in regulation.

What will it take to reach price parity?

Reviews agree it needs cheaper animal-free media, higher cell densities, larger and better-designed bioreactors and lower capital costs. A 2024 scoping review concluded that, under the current technological paradigm, cultivated meat is unlikely to compete with conventional meat on cost.

What allergens are relevant?

Cultured meat carries the allergenic proteins of its species, so cultured chicken or fish cells carry the same proteins as the animal, and medium components may add others. Suppliers should list residual medium proteins and any growth factors, and buyers should treat species as an allergen question.